He previously served as CDER Deputy Center Director and, earlier, as a Clinical Team Leader in CDERs Office of New Drugs, Division of Psychiatry, where he led multidisciplinary review teams and contributed to regulatory science and policy development in psychiatric drug development
Over dozens of draws from one vial, this adds up
Thats why the smartest approach is not panic, but precision: knowing what these medications do, what they do not do, and what to monitor along the way
However, if you still find that youre bothered by side effects and you dont feel that the results youre experiencing are worth putting up with these side effects, then stopping the medication may be the right decision
PerkinElmer) set at 5 s shaking and 0.5 s reading
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin